Nanoscale Field Effect Transistors have emerged as a promising technology for ultrasensitive, unlabeled diagnostic applications. However, their use as quantitative sensors has been problematic because of the need for individual sensor calibration. In this work we demonstrate an internal calibration scheme for multiplexed nanoribbon field effect sensors by utilizing the initial current rates rather than end point detection. A linear response is observed consistent with initial binding kinetics. Moreover, we are able to show that top-down fabrication techniques yield reproducible device results with minimal fluctuations, enabling internal calibration.
Introduction
Nanowire Field Effect Transistor (FET) sensor technology has demonstrated tremendous potential for point-of-care (POC) applications and has been successfully used for detection of proteins (Cui et al., 2001) , oligonucleotide sequences (Zhang et al., 2008) , cellular function (Stern et al., 2008) , virus detection (Patolsky et al., 2004) and enzymatic activity (Stern et al., 2010a) . Electronic labelfree detection is based on nanosensor surface modification with specific receptors capable of recognizing and binding the desired target molecules. Upon binding, the nanosensor surface potential is changed due to the electric charge present on the bound molecule, which modulates the nanosensor surface potential and thus causes an increase or decrease of carriers and device current (Bergveld, 1981) .
While several qualitative studies have demonstrated the true power of this detection method, the lack of quantitative results diminishes the competitiveness of the BioFET technology with the existing state-of-the-art techniques. A number of previous experiments have been performed on "bottom-up" or chemical vapour deposition (CVD) grown nanowires, but this method suffers from large device-to-device variation in electrical parameters such as threshold voltage, mobility and transconductance (Ishikawa et al., 2009) . Given these fluctuations, individual device calibration is thus required for quantitative analysis, thus eliminating one of the primary advantages of a microfabrication approach, i.e. multiplexing.
In order to minimize the variations of sensor electrical properties and sensing signal, two different approaches are used. One of them, uses device solution transconductance, g m,sol to normalize the total current change, I (Ishikawa et al., 2009; Stern et al., 2010a) caused by analyte binding, while the other applies a normalization by device baseline current level, I 0 , established prior to analyte addition (Bunimovitch et al., 2006) . However, all these methods use bottom-up grown nanowire which are problematic because of their nonuniform characteristics (Stern et al., 2005) .
In this work we demonstrate multiplexed sensing of cancer antigens and calibration of Silicon-On-Insulator (SOI) nanoribbon BioFETs fabricated using traditional lithographic methods. The top-down method accounts for the uniformity of device electrical characteristics which gives sensing repeatability and reproducibility. This aspect enables multiplexing, which allows for simultaneous data acquisition with better statistical analysis. The nanosensor surface is modified with capture antibodies which allow specific recognition of target biomarkers. Instead of using end-point detection to quantify device response, we instead measured initial rate, which has been shown using surface plasmon resonance (SPR) for antigen-antibody interactions to be linearly dependent on the analyte concentration (Homola, 2003) . Furthermore, we show that initial current rate scales linearly with both device baseline current and solution transconductance, supporting 0956-5663/$ -see front matter © 2011 Elsevier B.V. All rights reserved. doi:10.1016/j.bios.2011.07.025 the claim of using device electrical parameters for sensor calibration and suppression of device-to-device variation. Using the proposed method, we demonstrated universal calibration curve for device response, for a given biomarker. We conclude by presenting a blind test measurement performed to demonstrate the validity of the internal calibration standard.
Materials and methods
Silicon nanoribbon devices are fabricated from Silicon-onInsulator (SOI) wafers in a process similar to the one previously described (Stern et al., 2010b) . Nanosensor mesas were defined by chlorine reactive ion etching of 4 (100) SOI wafers with 25-35 nm of active Si layer (resistivity 1-10 cm) and 145 nm of buried oxide and silicon handle used as a backgate. Following the backgate etch and BF 2 + implantation (Core Systems, Inc., dose 5 × 10 15 cm −2 , energy 8 keV, tilt 7 • ), devices were annealed using a Rapid Thermal Processor (RTP) at 1000 • C for 30 s for dopant activation. Metal contacts were formed by electron beam deposition of Ti/Al stack (5 nm/145 nm) and ohmic contacts were formed by an RTP annealing at 450 • C for 1 min with N 2 purge. Devices were protected using hard baked S1813 photoresist. A schematic of a device is shown in Fig. 1a . Dies (5 mm × 5 mm) were packaged using 28-pin ceramic headers (Spectrum Semiconductor Materials, Inc., model CSB02892). Multiplexed I-V and DC time measurements were done using custom made system using a National Instruments Data Acquisition Card and Keithley 2636 Dual Source Measure Unit.
Prior to protection layer deposition, devices were functionalized with 3-aminopropyltrietoxy silane (APTES) functionalization by immersing in 5% (v/v) solution of APTES in toluene in an inert atmosphere for 2 h. The devices were then baked in a vacuum oven for 4 h at 180 • C.
Antibody functionalization was performed after I-V screening. Prostate specific (PSA) and breast cancer antigens (CA15.3) were chosen for multiplexed detection and calibration. Receptors, anti-PSA and anti-CA15.3 were bound to the nanoribbon surface using N-hydroxysulfosuccinimide/1-ethyl-3-(3-dimethylaminoproypl)carbodiimide hydrochloride (NHS/EDC) chemistry in 1× phosphate buffer saline (PBS, Sigma) at pH 7.4 for 2 h (Selo et al., 1996) . Samples were then washed with 1× PBS and a blocking step was performed with 10% fetal bovine serum (FBS) for 30 min, followed by washing with sensing buffer (1 mM bicarbonate buffer at pH 9).
Sensing experiments were done in direct current (DC) regime with gate-source and drain-source voltages being V gs = −3 V and V ds = 0.2 V, respectively, reference Ag/AgCl electrode grounded and a sampling time of t s = 0.5 s between DC current measurements. In each sensing experiment devices were first measured in 5 l of buffer solution to confirm a stable baseline current, followed by the addition of 5 l of analyte solution, upon which the current was observed and recorded.
Results and discussion
Device characteristics were assessed by simultaneous measurement of up to 8 devices on a given die. Fig. 1b shows the I DS -V GS characteristics of a representative p-type accumulation mode device. Devices show relatively narrow threshold voltage distribution, with average V T = −2.3 V, standard deviation of 0.15 V and standard error of the mean of 0.014 V for sample of 106 devices. The distribution in threshold voltages is dominated by the nonuniform thickness of the active silicon layer (70 ± 10(3 ) nm) and variations in the thickness of the thinning dry oxide (up to 5%). Fig. 1c shows the variation of threshold voltage for a series of dies, and the corresponding wafer map. Even with the variations of thresh- old voltage across the entire wafer, we demonstrate results with less than 10% error (see below). In regions with minimal thickness fluctuations (wafer center), we obtain threshold voltage variations of 8 mV, standard error of the mean. The off current of dry devices is measured to be on the order 1-100 fA which yields good on/off current ratios of approximately 5-6 orders of magnitude. The average subthreshold swing is (630 ± 60) mV/dec which is the consequence of 145 nm thick buried oxide layer between the active silicon layer and the backgate. The average drift mobility obtained from peak transconductance is calculated to be (93 ± 17) cm 2 /Vs which is in agreement with previously obtained values measured on fully depleted SOI RIE defined devices (Habicht et al., 2010) .
Bonded chips integrated with a fluidic mixing chamber (Stern et al., 2007) were functionalized with CA15.3 and PSA specific antibodies (anti-CA15.3 and anti-PSA, respectively) using NHS/EDC chemistry. Prior to analyte addition (CA15.3 or PSA), 5 l of sensing buffer was left in the mixing chamber and a baseline current I 0 was measured. This was followed by the addition of 5 l of analyte solution upon which the current I ds was recorded as a function of time. Current rate was calculated numerically from recorded data after data acquisition. Next we measured initial current rates which are directly proportional to the analyte concentration. Fig. 2 shows normalized simultaneous responses of 5 devices on the same chip upon the addition of 5 l solution of 9.5 U/ml CA15.3. Device signals were normalized using their baseline currents established prior to analyte injection. Fig. 3 shows that initial current rates are, as expected, linearly proportional to device electrical parameters, i.e. baseline current, therefore confirming the validity of our method. FET current and transconductance are given by
2 , saturation region and
, respectively, where v g is the reference gate potential and v T is the device pre-sensing threshold voltage. The baseline current i ds0 and transconductance g m0 prior to analyte addition are linearly related by
where ˛ = 1, lin. reg. 1/2, sat. reg.
, which implies that normalizations by device baseline current i ds0 and by transconductance g m0 would yield the same results if the term v g − v T does not change significantly between devices. In prior work (Ishikawa et al., 2009 ) it was found that the scaling was better for transconductance normalization versus baseline current normalization. This is because the initial current normalization is given by
where I is the current change caused by the equivalent gating potential v of the absorbed biomolecules, and v T is the threshold voltage of the device. Similarly, the transconductance scaling is given by I/(dI ds /dV g ) = v T . In the approach presented here the variation of v T is insignificant (14 mV SEM with |v T | = 2.3 V, or < 1%), and thus initial current rate or transconductance scaling gives equivalent results. Measurements were repeated multiple times on different dies using different dilutions of the 9.5 U/ml stock solution. A similar procedure was repeated for PSA detection using the serial dilutions of 10 ng/ml. Applying the described normalizing method for the three analyte concentrations one can plot calibrations curves, as shown in Fig. 4a and b for PSA and CA15.3, respectively. The device response is linear in the clinically relevant concentration range (1-10 ng/ml for PSA, 1-10 U/ml for CA15.3) (Vizcarra et al., 1996; Wu et al., 2001) . Even though the absolute errors of the stock solution concentrations, as determined by ELISA, were relatively large (15-20% for PSA and 40% for CA15.3), the variation of device responses was less than 10% (in terms of the standard error of the mean, SEM). Each data point represents an average over multiple (7-10) devices. Both fits have correlation coefficients R > 0.98. Table 1 summarizes the calibration results obtained for PSA and CA15.3 and demonstrates the relative standard error of the mean to be less than 10%.
In addition, we tested the calibration method using a blind measurement on a single device and a different measurement setup (red circle, Fig. 4a ) and compared it to the calibrated data. Upon introducing a concentration of (0.4 ± 0.08) ng/ml of PSA (determined by conventional ELISA) we measured a normalized current rate of 1.0054 × 10 −4 s −1 . Using the calibration curve shown in Fig. 4a we calculated the expected value to be (0.46 ± 0.06) ng/ml. This measurement deviates from the concentration obtained using conventional ELISA by approximately 15%.
Conclusion
Here we demonstrate a novel method for internal calibration of nanoscale FETs and use it for quantification of clinically relevant analytes, i.e. cancer biomarkers PSA and CA15.3. This approach is enabled by the ability of the CMOS-compatible fabrication approach we have developed to produce devices with very similar transport characteristics. We use initial kinetic rates, which are directly proportional to the analyte concentrations (assuming an initial unused sensor 1 ) rather than the endpoint detection. Measured calibration curves show a linear response in the relevant concentration ranges as well as good agreement with a blind measurement. In addition, we demonstrate that calibration by baseline current normalization is equivalent to that obtained by transconductance normalization. Our results demonstrate that nanosensors fabricated by conventional CMOS compatible processes yield reproducible results traceable to a calibration standard. We believe that this approach will make nanoscale FET sensor technology a step closer to commercial point-of-care applications.
